The company highlighted its progress in clinical development, particularly regarding brilaroxazine, a treatment for schizophrenia. The FDA has provided clear guidance, recommending a second Phase 3 trial to gather additional efficacy and safety data before the New Drug Application (NDA) submission. Reviva's current data package indicates a well-tolerated long-term safety profile and broad-spectrum clinical activity for brilaroxazine, which is expected to initiate the RECOVER-2 registrational trial in mid-2026.
In addition to clinical advancements, Reviva has successfully completed public equity offerings, raising a total of $29 million in 2025 and early 2026, which will support ongoing research and development activities. As of March 2026, the company reported cash and cash equivalents of approximately $23 million, which is expected to fund operations into the first quarter of 2027.
Reviva's strategic focus remains on addressing unmet medical needs in central nervous system disorders, inflammatory diseases, and cardiometabolic conditions. The company is committed to disciplined execution and aims to bring its promising therapies toward regulatory approval. With a strong clinical package and a favorable treatment adherence profile, Reviva is well-positioned to make significant strides in the pharmaceutical landscape.
